Tarek Mahdy1, Sameh Hany Emile2, Amr Madyan1, Carl Schou3, Abdulwahid Alwahidi4, Rui Ribeiro5, Alaa Sewefy6, Martin Büsing7, Mohammed Al-Haifi8, Emad Salih9, Scott Shikora10. 1. General Surgery Department, Mansoura Faculty of Medicine, Mansoura University Hospitals, Mansoura University, 60 El-Gomhoria Street Dakahlia, Mansoura, 35516, Egypt. 2. General Surgery Department, Mansoura Faculty of Medicine, Mansoura University Hospitals, Mansoura University, 60 El-Gomhoria Street Dakahlia, Mansoura, 35516, Egypt. Sameh200@hotmail.com. 3. Aker University Hospital, Oslo, Norway. 4. Sharjah University Hospital, Sharjah, United Arab Emirates. 5. Clinica De Santo Antonio, Lusiadas, Amadora, Lisbon, Portugal. 6. General Surgery Department, Minia Faculty of Medicine, Minia University, Minya, Egypt. 7. Klinikum Vest, Dorstenerstr, 151, 45657, Recklinghausen, Germany. 8. Sidra Hospital, Riggae Area, Kuwait. 9. Atakent Hospital, Istanbul, Turkey. 10. Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Abstract
BACKGROUND: Single anastomosis sleeve ileal (SASI) bypass is a newly introduced bariatric and metabolic procedure. The present multicenter study aimed to evaluate the efficacy of the SASI bypass in the treatment of patients with morbid obesity and the metabolic syndrome. METHODS: This is a retrospective, seven-country, multicenter study on patients with morbid obesity who underwent the SASI bypass. Data regarding patients' demographics, body mass index (BMI), percentage of total weight loss (%TWL), percentage of excess weight loss (%EWL), and improvement in comorbidities at 12 months postoperatively and postoperative complications were collected. RESULTS: Among 605 patients who underwent the SASI, 54 were excluded and 551 (390; 70.8% female) were included. At 12 months after the SASI, a significant decrease in the BMI was observed (43.2 ± 12.5 to 31.2 ± 9.7 kg/m2; p < 0.0001). The %TWL was 27.4 ± 13.4 and the %EWL was 63.9 ± 29.5. Among the 279 patients with type 2 diabetes mellitus (T2DM), complete remission was recorded in 234 (83.9%) patients and partial improvement in 43 (15.4%) patients. Eighty-six (36.1%) patients with hypertension, 104 (65%) patients with hyperlipidemia, 37 (57.8%) patients with sleep apnea, and 70 (92.1%) patients with GERD achieved remission. Fifty-six (10.1%) complications and 2 (0.3%) mortalities were recorded. Most complications were minor. All patients had 12 months follow-up. CONCLUSIONS: The SASI bypass is an effective bariatric and metabolic surgery that achieved satisfactory weight loss and improvement in medical comorbidities, including T2DM, hypertension, sleep apnea, and GERD, with a low complication rate.
BACKGROUND: Single anastomosis sleeve ileal (SASI) bypass is a newly introduced bariatric and metabolic procedure. The present multicenter study aimed to evaluate the efficacy of the SASI bypass in the treatment of patients with morbid obesity and the metabolic syndrome. METHODS: This is a retrospective, seven-country, multicenter study on patients with morbid obesity who underwent the SASI bypass. Data regarding patients' demographics, body mass index (BMI), percentage of total weight loss (%TWL), percentage of excess weight loss (%EWL), and improvement in comorbidities at 12 months postoperatively and postoperative complications were collected. RESULTS: Among 605 patients who underwent the SASI, 54 were excluded and 551 (390; 70.8% female) were included. At 12 months after the SASI, a significant decrease in the BMI was observed (43.2 ± 12.5 to 31.2 ± 9.7 kg/m2; p < 0.0001). The %TWL was 27.4 ± 13.4 and the %EWL was 63.9 ± 29.5. Among the 279 patients with type 2 diabetes mellitus (T2DM), complete remission was recorded in 234 (83.9%) patients and partial improvement in 43 (15.4%) patients. Eighty-six (36.1%) patients with hypertension, 104 (65%) patients with hyperlipidemia, 37 (57.8%) patients with sleep apnea, and 70 (92.1%) patients with GERD achieved remission. Fifty-six (10.1%) complications and 2 (0.3%) mortalities were recorded. Most complications were minor. All patients had 12 months follow-up. CONCLUSIONS: The SASI bypass is an effective bariatric and metabolic surgery that achieved satisfactory weight loss and improvement in medical comorbidities, including T2DM, hypertension, sleep apnea, and GERD, with a low complication rate.
Authors: Emma Spak; Per Björklund; Herbert F Helander; Michael Vieth; Torsten Olbers; Anna Casselbrant; Hans Lönroth; Lars Fändriks Journal: Histopathology Date: 2010-11-03 Impact factor: 5.087
Authors: Nicola Scopinaro; Giuseppe Maria Marinari; Giovanni Bruno Camerini; Francesco Saverio Papadia; Gian Franco Adami Journal: Diabetes Care Date: 2005-10 Impact factor: 19.112
Authors: F Favretti; G B Cadiere; G Segato; J Himpens; L Busetto; F De Marchi; M Vertruyen; G Enzi; M De Luca; M Lise Journal: Obes Surg Date: 1997-08 Impact factor: 4.129
Authors: Richard D Carr; Marianne O Larsen; Maria Sörhede Winzell; Katarina Jelic; Ola Lindgren; Carolyn F Deacon; Bo Ahrén Journal: Am J Physiol Endocrinol Metab Date: 2008-07-08 Impact factor: 4.310
Authors: K R Angevine; L M Wuescher; K Andrews; L A Alexander; M F McInerney; T J Kieffer; E J Mensah-Osman Journal: Nutr Diabetes Date: 2012-12-03 Impact factor: 5.097
Authors: Wiesław Tarnowski; Krzysztof Barski; Paweł Jaworski; Artur Binda; Emilia Kudlicka; Michał Wąsowski; Piotr Jankowski Journal: Wideochir Inne Tech Maloinwazyjne Date: 2022-03-25 Impact factor: 1.627